Insulin
Approved · EMAAlso known as Afrezza, High molecular weight insulin human, Human insulin, Human insulin soluble+22 more
Afrezza, High molecular weight insulin human, Human insulin, Human insulin soluble, Human regular insulin, HumuLIN R, Humulin, INSULIN HUMAN, Insulin (human), Insulin Human Regular, Insulin regular, Insulin, human, Insulina regular, Myxredlin, NovoLIN R, Novolin, Regular Insulin, human, Velosulin BR, insulin regular, human, INSULIN,REGULAR,HUMAN/SEMISYNTHETIC, INSULIN,REGULAR,HUMAN/rDNA, Insulin human regular (rDNA), ReliOn/HumuLIN R, insulin regular human recombinant, insulin regular, human semi-synthetic, insulin, regular, human.
Recent clinical, regulatory, research and industry developments relating to this drug.
STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing
STAT+: Popular insulin product enters shortage as other pens leave market
What comparative endocrinology tells us about the original function of the insulin superfamily.
Hippocampal-Specific Insulin Resistance Elicits Synaptic Effects on Glutamate Neurotransmission.
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving… Show full indicationShow less
Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Diabetes8
- International journal of molecular sciences8
- The Journal of clinical investigation8
- Nature communications6
- Frontiers in endocrinology4
- Cardiovascular diabetology3
- Holst JJ7
- Drucker DJ5
- Nauck MA5
- Müller TD4
- Bie-Olsen LG3
- Kadowaki T3
- Kjaer TW3
- Law I3
- University of Copenhagen5
- Institute for Diabetes and Obesity4
- School of Medicine4
- University of California4
- Baylor College of Medicine3
- German Center for Diabetes Research (DZD)3
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 21 of the same disease areas as Insulin in the shared literature.
Studied across 17 of the same disease areas as Insulin in the shared literature.
Studied across 19 of the same disease areas as Insulin in the shared literature.
Studied across 21 of the same disease areas as Insulin in the shared literature.
Studied across 27 of the same disease areas as Insulin in the shared literature.
Studied across 14 of the same disease areas as Insulin in the shared literature.
Studied across 14 of the same disease areas as Insulin in the shared literature.
Studied across 17 of the same disease areas as Insulin in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.